@article {Kuhne2454作者={伊丽莎白·库恩和奥黛丽Perrotin Renaud La乐趣和雪绒花Touron苏菲Dautricourt和马修Vanhoutte丹尼斯薇薇安和文森特de La Sayette Ga {\“e} l Ch {\ ' e} telat和{\ textquoteright}年代老年痴呆症神经影像倡议},title ={协会Informant-Reported与认知和大脑记忆衰退恶化通过老年痴呆症临床连续},体积={100}={24},页面= {e2454——e2465} = {2023}, doi = {10.1212 / WNL。出版商0000000000207338}= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={背景和目标研究稀疏关于之间的关联informant-reported主观记忆衰半岛投注体育官网退(线人报告)和阿尔茨海默病(AD)生物标记。因此本研究旨在确定的临床相关性线人报告整个广告临床连续体,通过评估其特定的与淀粉样蛋白沉积的关系,认知和神经退化。方法从Imagerie参与者Multimodale de la病d {\ textquoteright}{\ '}联合国老年痴呆症施塔德公关{\ ' e} coce (IMAP +)初级群体和阿尔茨海默病神经影像倡议(ADNI)复制队列中;进行了多通道神经影像学和神经心理评估。后续数据IMAP +参与者/ 36个月也用于纵向分析。线人报告测量的认知困难量表(IMAP +)和日常认知(ADNI)。一般线性模型被用来评估之间的横向联系线人报告和淀粉pet,认知表现,和神经退行性变的老年痴呆症的签名(萎缩和代谢减退);而纵向联系在IMAP +线性mixed-effects模型评估。结果总共包括110 IMAP +参与者,包括32个认知未受损伤的老年人(控制、年龄:70.91 {\ textpm} 6.57岁,女:50 \ %),25名患者主观认知能力下降(SCD, 65.88 {\ textpm} 6.64, 40 \ %), 35岁患有轻度认知障碍(MCI, 72.49 7.5 {\ textpm}, 34 \ %),和18 Alzheimer-type痴呆(AD痴呆,68.17 {\ textpm} 8.59, 28 \ %)。七百三十一包括ADNI参与者,包括157名对照(74.21 {\ textpm} 5.95, 55 \ %), 84年SCD (72.00 5.41 {\ textpm}, 63 \ %), 369年与MCI (71.84 {\ textpm} 7.4, 44 \ %),和121 AD痴呆(74.29 {\ textpm} 7.75, 40 \ %)。 In IMAP+, a higher informant report strongly correlated to greater amyloid-PET, specifically in patients with MCI (β = 0.48, p = 0.003), and to lower cognitive performance in patients with SCD (global cognition, β = -0.41, p = 0.04) and MCI (memory, β = -0.37, p = 0.03). Findings in patients with MCI were replicated in the ADNI (amyloid-PET, β = 0.25, p \< 0.001; memory, β = -0.22, p \< 0.001) and extended to neurodegeneration in AD signature areas (β = -0.2, p \< 0.001). Longitudinal analyses in IMAP+ showed links with global cognitive decline over time in patients with MCI (estimate -0.74, SE 0.26, p = 0.005) and SCD (estimate -0.36, SE 0.26, p = 0.02) where a higher baseline informant report also predicted an increased amyloid-PET over time (estimate 0.008, SE 0.003, p = 0.02).Discussion Altogether, our findings suggest that the informant report is particularly relevant in patients with MCI where it strongly relates to higher amyloid-PET, indicative of impairment due to AD.Trial Registration Information ClinicalTrials.gov Identifier: NCT01638949.AD dementia=Alzheimer-type dementia; ADNI=Alzheimer Disease Neuroimaging Initiative; CDS=Cognitive Difficulties Scale; CU=cognitively unimpaired; ESR=Encoding, Storage, and Retrieval; FDG=18F-fluorodeoxyglucose; FDR=false discovery rate; FLAIR=fluid-attenuated inversion recovery; GM=gray matter; IMAP+=Imagerie Multimodale de la maladie d{\textquoteright}Alzheimer {\`a} un stade Pr{\'e}coce; I-SMD=Informant-reported Subjective Memory Decline; MCI=mild cognitive impairment; MMSE=Mini-Mental State Examination; SCD=subjective cognitive decline; Self-SMD=self-reported Subjective Memory Decline; SUVr=global neocortical standardized uptake value ratio}, issn = {0028-3878}, URL = {//www.ebmtp.com/content/100/24/e2454}, eprint = {//www.ebmtp.com/content/100/24/e2454.full.pdf}, journal = {Neurology} }